{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"88.9"},{"groupId":"OG003","value":"100.0"}]}],"title":"Cycle 1 Day 1 (Anti-E7777 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"83.3"},{"groupId":"OG003","value":"0"}]}],"title":"Cycle 2 Day 1 (Anti-E7777 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"0"}]}],"title":"Cycle 3 Day 1 (Anti-E7777 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"0"}]}],"title":"Cycle 5 Day 1 (Anti-E7777 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"37.5"},{"groupId":"OG002","value":"33.3"},{"groupId":"OG003","value":"0"}]}],"title":"Cycle 1 Day 1 (Anti-IL-2 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"87.5"},{"groupId":"OG002","value":"83.3"},{"groupId":"OG003","value":"0"}]}],"title":"Cycle 2 Day 1 (Anti-IL-2 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"0"}]}],"title":"Cycle 3 Day 1 (Anti-IL-2 Antibodies)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"83.3"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"0"}]}],"title":"Cycle 5 Day 1 (Anti-IL-2 Antibodies)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"description":"Immunogenicity was assessed by determining the anti-E7777 and anti-IL-2 antibodies in serum using validated methods. Percentage of participants testing positive for Anti-E7777 and Anti-IL-2 antibodies were reported.","groups":[{"description":"Participants were treated with E7777 6 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG000","title":"Lead-In Part: E7777 6 mcg/kg"},{"description":"Participants were treated with E7777 9 mcg/kg by IV infusion over 60 minute on 5 consecutive days during every 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-In Part.","id":"OG001","title":"Lead-In Part: E7777 9 mcg/kg"},{"description":"Participants were treated with E7777 12 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG002","title":"Lead-In Part: E7777 12 mcg/kg"},{"description":"Participants were treated with E7777 15 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG003","title":"Lead-In Part: E7777 15 mcg/kg"}],"paramType":"NUMBER","populationDescription":"Lead-in PK Analysis Set included all participants who received at least one dose of study drug and from whom at least one valid E7777 PK parameter was obtained.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 5 Day 1","title":"Lead-In Part: Percentage of Participants Testing Positive for Anti-E7777 and Anti-interleukin (IL)-2 Antibodies","type":"SECONDARY","unitOfMeasure":"percentage of participants"}